P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

Bibliographic Details
Main Authors:	S. Usmani, A. Hoering, S. Ailawadhi, R. Sexton, B. Lipe, J. Valent, M. Rosenzweig, J. Zonder, M. Dhodapkar, N. Callander, T. Zimmerman, P. Voorhees, B. Durie, S. V. Rajkumar, P. Richardson, R. Orlowski
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846728.05693.f8

Internet